Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Th...
November 15 2016 - 7:30AM
Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage
biopharmaceutical company developing precision medicines for
cancer, today announced it will be presenting two posters at the
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics (ENA 2016), taking place November 29 – December 2,
2016 in Munich. The presentations will feature preclinical
data from Kura Oncology’s KO‒947 ERK inhibitor and menin-MLL
inhibitor programs. Abstracts are currently available online
at the European Cancer Organisation website
(www.ecco-org.eu/Events/ENA2016).
PostersDate & Time: Nov. 30, 2016, 10:15 a.m. - 5:00 p.m.
(CET)Poster Title: Discovery of novel menin-MLL small molecule
inhibitors that display high potency and selectivity in vitro and
in vivoSession: Epigenetic modulatorsAbstract Number: 264 Poster
Location: P090, ICM – Internationales Congress Center München
Date & Time: Dec. 1, 2016, 10:15 a.m. - 5:00 p.m.
(CET)Poster Title: KO-947, a potent and selective ERK inhibitor
with slow dissociation kineticsSession: Molecular targeted agents
IIAbstract Number: 381Poster Location: P060, ICM – Internationales
Congress Center München
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecules that target cancer signaling pathways where there is a
strong scientific and clinical rationale to improve outcomes by
identifying those patients most likely to benefit from treatment.
Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl
transferase inhibitor, which is currently being studied in multiple
Phase 2 clinical trials. The preclinical pipeline includes KO-947,
an ERK inhibitor, and a menin-MLL program. For additional
information about Kura Oncology, please visit the company’s website
at www.kuraoncology.com.
CONTACT INFORMATION
INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
MEDIA CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024